Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: A nested case-control study

Lancet

Volumn 355, Issue 9222, 2000, Pages 2189-2193

  Josefsson, Agnetha M ^a   Magnusson, Patrik K E ^a   Ylitalo, Nathalie ^b   Sørensen, Per ^c,d   Qwarforth Tubbin, Pernilla ^a   Kragh Andersen, Per ^c,d   Melbye, Mads ^c   Adami, Hans Olov ^b,e   Gyllensten, Ulf B ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c S   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; VIRUS DNA;

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOLOGY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPILLOMA VIRUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD;

EID: 0034709683     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02401-6     Document Type: Article

References (27)

1. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer. 54:1993;594-606.
2. Bosch F.X., Manos M.M., Munoz M.M.et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 87:1995;796-802.
3. Brisson J., Morin C., Fortier M.et al. Risk factors for cervical intraepithelial neoplasia: differences between low- and high-grade lesions. Am J Epidemiol. 140:1994;700-710.
4. Cuzick J., Terry G., Ho L., Hollingworth T., Anderson M. Human papillomavirus type 16 in cervical smears as predictor of high- grade cervical intraepithelial neoplasia. Lancet. 339:1992;959-960.
5. Cuzick J., Terry G., Ho L., Hollingworth T., Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer. 69:1994;167-171.
6. Ho G.Y., Kadish A.S., Burk R.D.et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer. 78:1998;281-285.
7. Ho G.Y., Palan P.R., Basu J.et al. Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer. 78:1998;594-599.
8. Munoz N., Bosch F. HPV and cervical neoplasia: review of case-control and cohort studies. IARC Sci Publ. 119:1992;251-261.
9. Cox J.T., Lorincz A.T., Schiffman M.H., Sherman M.E., Cullen A., Kurman R.J. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 172:1995;946-954.
10. Terry G., Ho L., Jenkins D.et al. Definition of human papillomavirus type 16 DNA levels in low and high grade cervical lesions by a simple polymerase chain reaction technique. Arch Virol. 128:1993;123-133.
11. Ylitalo N., Sörensen P., Josefsson A.et al. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. Int J Cancer. 81:1999;357-365.
12. Josefsson A., Livak K., Gyllensten U. Detection and quantitation of human papillomavirus by using the fluorescent 5′ exonuclease assay. J Clin Microbiol. 37:1999;490-496.
13. Ylitalo N., Bergstrom T., Gyllensten U. Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization. J Clin Microbiol. 33:1995;1822-1828.
14. Holland P.M., Abramson R.D., Watson R., Gelfand D.H. Detection of specific polymerase chain reaction product by utilizing the 5′-3′ exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA. 88:1991;7276-7280.
15. Heid C.A., Stevens J., Livak K.J., Williams P.M. Real time quantitative PCR. Genome Res. 6:1996;986-994.
16. Lee L.G., Connell C.R., Bloch W. Allelic discrimination by nick-translation PCR with fluorogenic probes. Nucleic Acids Res. 21:1993;3761-3766.
17. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 102:1997;3-8.
18. Ho G.Y., Kadish A.S., Burk R.D.et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer. 78:1998;281-285.
19. Zehbe I., Wilander E., Delius H., Tommasino M. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 58:1998;829-833.
20. Londesborough P., Ho L., Terry G., Cuzick J., Wheeler C., Singer A. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer. 69:1996;364-368.
21. Magnusson P.K.E., Sparen P., Gyllensten U.B. Genetic link to cervical tumours. Nature. 400:1999;29-30.
22. Hildesheim A., Schiffman M., Scott D.R.et al. Human leukocyte antigen class I/II alleles and development of human papillomavirus-related cervical neoplasia: results from a case-control study conducted in the United States. Cancer Epidemiol Biomarkers Prev. 7:1998;1035-1041.
23. Odunsi K., Terry G., Ho L., Bell J., Cuzick J., Ganesan T.S. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLA DR-DQ alleles. Int J Cancer. 67:1996;595-602.
24. Allen M., Kalantari M., Ylitalo N., Pettersson B., Hagmar B., Scheibenpflug L. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens. 48:1996;32-37.
25. Apple R.J., Becker T.M., Wheeler C.M., Erlich H.A. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. Natl Cancer Inst. 87:1995;427-436.
26. Ho G.Y., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 338:1998;423-428.
27. Ylitalo N., Sørensen P., Josefsson A.et al. Consistent high viral load of human papillomavrus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet. 355:2000;2194-2198.